To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.

Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Division Vote (Commons)
8 Dec 2025 - Employment Rights Bill - View Vote Context
Steve Barclay (Con) voted No - in line with the party majority and against the House
One of 84 Conservative No votes vs 0 Conservative Aye votes
Vote Tally: Ayes - 300 Noes - 96
Division Vote (Commons)
8 Dec 2025 - Employment Rights Bill - View Vote Context
Steve Barclay (Con) voted No - in line with the party majority and against the House
One of 84 Conservative No votes vs 0 Conservative Aye votes
Vote Tally: Ayes - 327 Noes - 162
Division Vote (Commons)
8 Dec 2025 - Employment Rights Bill - View Vote Context
Steve Barclay (Con) voted No - in line with the party majority and against the House
One of 86 Conservative No votes vs 0 Conservative Aye votes
Vote Tally: Ayes - 395 Noes - 98
Division Vote (Commons)
8 Dec 2025 - Employment Rights Bill - View Vote Context
Steve Barclay (Con) voted No - in line with the party majority and against the House
One of 86 Conservative No votes vs 0 Conservative Aye votes
Vote Tally: Ayes - 327 Noes - 96
Division Vote (Commons)
3 Dec 2025 - Pension Schemes Bill - View Vote Context
Steve Barclay (Con) voted Aye - in line with the party majority and against the House
One of 75 Conservative Aye votes vs 0 Conservative No votes
Vote Tally: Ayes - 154 Noes - 303
Division Vote (Commons)
3 Dec 2025 - Pension Schemes Bill - View Vote Context
Steve Barclay (Con) voted Aye - in line with the party majority and against the House
One of 74 Conservative Aye votes vs 0 Conservative No votes
Vote Tally: Ayes - 143 Noes - 304
Speech in Commons Chamber - Wed 03 Dec 2025
Ely: Railway Upgrade

"The Minister seems to be citing a lack of funding as the reason for the scheme not being funded, but when I spoke to the Rail Minister in his previous role as chair of Network Rail, it was a priority for Network Rail. Can the Minister confirm from the Dispatch …..."
Steve Barclay - View Speech

View all Steve Barclay (Con - North East Cambridgeshire) contributions to the debate on: Ely: Railway Upgrade
Speech in Commons Chamber - Wed 03 Dec 2025
Ely: Railway Upgrade

"What about the BCR?..."
Steve Barclay - View Speech

View all Steve Barclay (Con - North East Cambridgeshire) contributions to the debate on: Ely: Railway Upgrade
Speech in Commons Chamber - Wed 03 Dec 2025
Ely: Railway Upgrade

"I congratulate the hon. Lady on securing the debate. I very much support the case she is making. Given that the previous Government, in October 2023, did secure funding for this, it is deeply regrettable that the Labour Government have cut it. Does she agree that if we are to …..."
Steve Barclay - View Speech

View all Steve Barclay (Con - North East Cambridgeshire) contributions to the debate on: Ely: Railway Upgrade
Written Question
Cancer: Medical Treatments
Tuesday 2nd December 2025

Asked by: Steve Barclay (Conservative - North East Cambridgeshire)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what is being done to improve the regulatory approval process for personalised medicines to treat cancer.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The Medicines and Healthcare products Regulatory Agency (MHRA) has completed a public consultation on its draft guideline on individualised mRNA cancer immunotherapies, a new type of personalised cancer treatment. These technologies use cutting-edge science such as artificial intelligence to design a medicine tailored to each patient’s unique tumour profile.

We received positive responses from across the life sciences community, the National Health Service, patient groups, academics, and international regulators. Feedback recognised the United Kingdom’s leadership in this area, while calling for greater clarity in some aspects of the guideline.

In response, we will refine the guideline to ensure regulatory expectations are clearly articulated, without hampering innovation. This will facilitate faster access to these promising new therapies, while upholding our standards of safety, quality, and efficacy. The final version of the guideline will be published in the coming months, with future updates anticipated as the regulatory experience evolves in this rapidly developing field.